X-twitter Linkedin Facebook-f Vimeo

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

BIOG

Biotech Growth secures major value from Forte Biosciences takeover

Biotech Growth is set to benefit from Argenx’s $2.2 billion acquisition of Forte Biosciences after entering the company at a much lower valuation...
Cizzle Biotechnology Holdings plc

Cizzle Biotechnology begins US commercial launch of lung cancer blood test

Cizzle Biotechnology has started the US commercial rollout of its CIZ1B lung cancer blood test through an initial launch in Texas...
Genflow Biosciences Plc

Genflow nears key data readout for SIRT6 gene therapy platform

Genflow is nearing a key data point as it combines animal study results, specialist RNA delivery support and broader patent protection...
Verici Dx Plc

Verici Dx adds senior transplant experts to support clinical development

Verici Dx has expanded its Scientific Advisory Board with 14 senior transplant and clinical research specialists to support product development and adoption...
SN

Smith & Nephew maintains profit guidance as H1 trading margin improves

Smith & Nephew reported higher half-year revenue, operating profit and cash generation, while reducing full-year revenue guidance...
CIZ

Cizzle Bio signs second US laboratory agreement for lung cancer blood test

Cizzle Bio has partnered with BioBridge Global to validate and offer the CIZ1B Biomarker Blood Test through a CLIA-certified laboratory serving healthcare providers across South Texas...
Genflow Biosciences Plc

Genflow Biosciences links ageing science with MASH research

MASH gives Genflow Biosciences a defined opportunity to explore how its SIRT6-based gene therapy research could address metabolic liver damage, inflammation and fibrosis...
EDX Medical Group plc

EDX Medical Group deploys rapid pneumonia test at Addenbrooke’s ICU

EDX Medical Group has said its rapid pneumonia test is now in NHS clinical practice and has benefited patients at Addenbrooke's Hospital...
GENF

Genflow Biosciences advances SIRT6 patent portfolio in US and Europe

Genflow Biosciences has reported progress on its SIRT6 patent families, including a published US application and Track One examination...
HLN

Haleon reports half-year results and declares interim dividend

Haleon has announced its half-year results, declared a 2.4 pence interim dividend and provided details of its investor presentation...
Verici Dx Plc

Verici Dx strengthens medical leadership to support transplant diagnostics strategy

Verici Dx has appointed experienced diagnostics executive Paul Pagano as Chief of Medical Affairs to strengthen clinical evidence, scientific engagement and the development of its transplant diagnostics portfolio...
Genflow Biosciences Plc

Genflow Biosciences moves longevity programme towards its next test

Genflow Biosciences has reported better survival rates and no adverse events three months into its ageing-dog gene therapy study...
BIOG

Biotech Growth Trust targets undervalued innovation

The Trust is focusing on undervalued biotech companies with strong clinical potential, takeover appeal and exposure to new medical innovation...
BIOG

Biotech Growth Trust notes $2.2 billion acquisition of Forte Biosciences

Argenx has agreed to acquire BIOG portfolio company Forte Biosciences for $77 per share in cash, representing a 40.5% premium. Forte accounted for 3.03% of the Company’s NAV at the..
AZN

AstraZeneca H1 2026 revenue rises 9% as growth momentum continues

AstraZeneca reported first-half 2026 revenue of $30.7 billion, up 6% at constant exchange rates, with core operating profit and core EPS both rising 11%. Growth in oncology and rare disease..
intravenous (IV) line

Astrazeneca reports positive survival data for Sone-Ve in gastric cancer trial

Astrazeneca Plc has reported statistically significant overall survival results for Sone-Ve in the CLARITY-Gastric01 Phase III trial...
EDX Medical Group plc

Professor Sir Chris Evans outlines EDX Medical’s new workplace health screening service

EDX Medical’s Chief Scientific Officer discusses the service’s on-site testing model, competitive advantages, employer demand and potential to generate more than £2 million this financial year...
AstraZeneca

Astrazeneca secures EU approval for Etcamah in ER-positive breast cancer

Astrazeneca Plc has secured European Union approval for Etcamah in combination therapy for ER-positive, HER2-negative advanced breast cancer...
BIOG

Biotech Growth Trust offers broad access to global drug innovation

A globally diversified biotechnology trust focused on strong science, clear catalysts and long-term growth opportunities...
Verici Dx Plc

Verici Dx gains greater reimbursement clarity for transplant diagnostics

The final MolDx policy gives Verici Dx clearer reimbursement conditions for transplant testing from late August 2026...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

BIOG

Biotech Growth secures major value from Forte Biosciences takeover

Biotech Growth is set to benefit from Argenx’s $2.2 billion acquisition of Forte Biosciences after entering the company at a much lower valuation...
Cizzle Biotechnology Holdings plc

Cizzle Biotechnology begins US commercial launch of lung cancer blood test

Cizzle Biotechnology has started the US commercial rollout of its CIZ1B lung cancer blood test through an initial launch in Texas...
Genflow Biosciences Plc

Genflow nears key data readout for SIRT6 gene therapy platform

Genflow is nearing a key data point as it combines animal study results, specialist RNA delivery support and broader patent protection...
Verici Dx Plc

Verici Dx adds senior transplant experts to support clinical development

Verici Dx has expanded its Scientific Advisory Board with 14 senior transplant and clinical research specialists to support product development and adoption...
SN

Smith & Nephew maintains profit guidance as H1 trading margin improves

Smith & Nephew reported higher half-year revenue, operating profit and cash generation, while reducing full-year revenue guidance...
CIZ

Cizzle Bio signs second US laboratory agreement for lung cancer blood test

Cizzle Bio has partnered with BioBridge Global to validate and offer the CIZ1B Biomarker Blood Test through a CLIA-certified laboratory serving healthcare providers across South Texas...
Genflow Biosciences Plc

Genflow Biosciences links ageing science with MASH research

MASH gives Genflow Biosciences a defined opportunity to explore how its SIRT6-based gene therapy research could address metabolic liver damage, inflammation and fibrosis...
EDX Medical Group plc

EDX Medical Group deploys rapid pneumonia test at Addenbrooke’s ICU

EDX Medical Group has said its rapid pneumonia test is now in NHS clinical practice and has benefited patients at Addenbrooke's Hospital...
GENF

Genflow Biosciences advances SIRT6 patent portfolio in US and Europe

Genflow Biosciences has reported progress on its SIRT6 patent families, including a published US application and Track One examination...
HLN

Haleon reports half-year results and declares interim dividend

Haleon has announced its half-year results, declared a 2.4 pence interim dividend and provided details of its investor presentation...
Verici Dx Plc

Verici Dx strengthens medical leadership to support transplant diagnostics strategy

Verici Dx has appointed experienced diagnostics executive Paul Pagano as Chief of Medical Affairs to strengthen clinical evidence, scientific engagement and the development of its transplant diagnostics portfolio...
Genflow Biosciences Plc

Genflow Biosciences moves longevity programme towards its next test

Genflow Biosciences has reported better survival rates and no adverse events three months into its ageing-dog gene therapy study...
BIOG

Biotech Growth Trust targets undervalued innovation

The Trust is focusing on undervalued biotech companies with strong clinical potential, takeover appeal and exposure to new medical innovation...
BIOG

Biotech Growth Trust notes $2.2 billion acquisition of Forte Biosciences

Argenx has agreed to acquire BIOG portfolio company Forte Biosciences for $77 per share in cash, representing a 40.5% premium. Forte accounted for 3.03% of the Company’s NAV at the time of the announcement...
AZN

AstraZeneca H1 2026 revenue rises 9% as growth momentum continues

AstraZeneca reported first-half 2026 revenue of $30.7 billion, up 6% at constant exchange rates, with core operating profit and core EPS both rising 11%. Growth in oncology and rare disease offset Farxiga and China headwinds. The company raised its interim dividend, secured 30 approvals, and reaffirmed full-year guidance and its $80 billion 2030 revenue goal...
intravenous (IV) line

Astrazeneca reports positive survival data for Sone-Ve in gastric cancer trial

Astrazeneca Plc has reported statistically significant overall survival results for Sone-Ve in the CLARITY-Gastric01 Phase III trial...
EDX Medical Group plc

Professor Sir Chris Evans outlines EDX Medical’s new workplace health screening service

EDX Medical’s Chief Scientific Officer discusses the service’s on-site testing model, competitive advantages, employer demand and potential to generate more than £2 million this financial year...
AstraZeneca

Astrazeneca secures EU approval for Etcamah in ER-positive breast cancer

Astrazeneca Plc has secured European Union approval for Etcamah in combination therapy for ER-positive, HER2-negative advanced breast cancer...
BIOG

Biotech Growth Trust offers broad access to global drug innovation

A globally diversified biotechnology trust focused on strong science, clear catalysts and long-term growth opportunities...
Verici Dx Plc

Verici Dx gains greater reimbursement clarity for transplant diagnostics

The final MolDx policy gives Verici Dx clearer reimbursement conditions for transplant testing from late August 2026...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple